Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Cellular Mechanisms of a New Pyrazinone Compound that Induces Apoptosis in SKOV-3 Cells

  • Wang, Guan (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University) ;
  • Jiang, Meng-Ying (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University) ;
  • Meng, Ying (Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University) ;
  • Song, Hong-Rui (Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University) ;
  • Shi, Wei (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University)
  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

We screened a small molecular library that was designed and independently synthesized in vitro and found a new drug (MY-03-01) that is active against ovarian cancer. We established that MY-03-01 effectively inhibited SKOV-3 cell survival in a dose-dependent manner, based on cell viability rates, and that it not only induced SKOV-3 apoptosis by itself, but also did so synergistically with paclitaxel. Secondly, when MY-03-01 was applied at $40{\mu}M$, its hemolytic activity was less than 10%, compared with the control, and there was almost no damage to nor mal cells at this concentration. In addition, we used DAPI staining and flow cytometry to show that MY-03-01 could significantly induce apoptosis of SKOV-3 cells. Finally, we found that MY-03-01 likely induced SKOV-3 apoptosis by activating caspase3 and caspase9 through the mitochondrial pathway.

Keywords

References

  1. Abuharbeid S, Apel J, Zugmaier G, et al (2005). Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol, 371, 141-1. https://doi.org/10.1007/s00210-004-1016-4
  2. Chauhan SC, Kumar D, Jaggi M (2009). Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res, 12, 21-9.
  3. Degterev A, Boyce M, Yuan J (2003). A decade of caspases. Onco- gene, 22, 8543-7. https://doi.org/10.1038/sj.onc.1207107
  4. Dejean LM, Martinez-Caballero S, Kinnally KW (2006). Is MAC the knife that cuts cytochrome c from mitochondria during apop-tosis? Cell Death Differ, 13, 1387-5. https://doi.org/10.1038/sj.cdd.4401949
  5. Descoteaux C, Brasseur K, Leblanc V, et al (2012). Design of novel tyrosinenitrogen mustard hybrid molecules active against uterine, ovarian and brea- st cancer cell lines. Steroids, 77, 403-2. https://doi.org/10.1016/j.steroids.2011.12.021
  6. du Bois A, Quinn M, Thigpen T, et al (2005). 2004 consensus stat- ements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian C-ancer Consensus Conference (GCIG OCCC 2004). Ann Oncol, 16, viii7-2.
  7. McGuire WP, Hoskins WJ, Brady MF, et al (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patpatients with stage III and stage IV ovarian cancer. N Engl J Med, 334, 1-6. https://doi.org/10.1056/NEJM199601043340101
  8. Meng Y, Wang G, Li Y, et al (2013). Synthesis and biolo-gical evaluation of new pyrrolopyrazinone compounds as potential antitumor agents. Chin Chem Lett, 24, 619-1. https://doi.org/10.1016/j.cclet.2013.04.020
  9. Metzger-Filho O, Moulin C, D'Hondt V (2010). First-line systemic treatment of ovarian cancer: a critical re'view of available eviden- ce and expectations for future directions. Curr Opin Oncol, 22, 513-0. https://doi.org/10.1097/CCO.0b013e32833ae99c
  10. Petrucci E, Pasquini L, Petronelli A, et al (2007). A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol, 105, 481-2. https://doi.org/10.1016/j.ygyno.2007.01.011
  11. Piotrowska H, Myszkowski K Ziolkowska A, et al (2012). Resver- atrol analogue 3,4,4',5-tetramethoxystilbene inhibits growth, arr-ests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol, 263, 53-0. https://doi.org/10.1016/j.taap.2012.05.023
  12. Rogalska A, Gajek A, Szwed M, Jozwiak Z, Marczak A (2011). T- he role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of do- xorubicin. Toxicol In Vitro, 25, 1712-0. https://doi.org/10.1016/j.tiv.2011.08.009
  13. Rogalska A, Marczak A, Gajek A, et al (2013). Induction of apopt-osis in human ovarian cancer cells by new anticancer compoun-ds, epothilone A and B. Toxicol In Vitro, 27, 239-9. https://doi.org/10.1016/j.tiv.2012.09.006
  14. Rouzier R, Bergzoll C, Brun JL, et al (2010). The role of lymph node resection in ovarian cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database. BJOG, 117, 1451-8. https://doi.org/10.1111/j.1471-0528.2010.02633.x
  15. Sachdeva MS (1998). Drug targeting systems for cancer chemothe- erapy. Expert Opin Investig Drugs, 7, 1849-4. https://doi.org/10.1517/13543784.7.11.1849
  16. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on prematurecacer deaths. CACancer J Clin, 61, 212-6. https://doi.org/10.3322/caac.20121
  17. Wagner U, du Bois A, Pfisterer J, et al (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinumtaxane based therapya phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol, 105, 132-7. https://doi.org/10.1016/j.ygyno.2006.10.053
  18. Wahl H, Tan L, Griffith K, Choi M, Liu JR (2007). Curcumin enhances nces Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol, 105, 104-2. https://doi.org/10.1016/j.ygyno.2006.10.050
  19. Zamboni WC, Strychor S, Joseph E (2008). Tumor, tissue, and pl-asma pharma cokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bear-ing SKOV-3 human ovarian xenografts. Cancer Chemother Pharmacol, 62, 417-6. https://doi.org/10.1007/s00280-007-0620-7
  20. Zhang Y, Ge Y, Chen Y, et al (2012). Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem Funct, 30, 243-8. https://doi.org/10.1002/cbf.1842

Cited by

  1. Anti-tumor Effects and Apoptosis Induction by Realgar Bioleaching Solution in Sarcoma-180 Cells in Vitro and Transplanted Tumors in Mice in Vivo vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2883
  2. AST IV inhibits H2O2-induced human umbilical vein endothelial cell apoptosis by suppressing Nox4 expression through the TGF-β1/Smad2 pathway vol.35, pp.6, 2015, https://doi.org/10.3892/ijmm.2015.2188